https://www.selleckchem.com/products/nu7441.html
7months; 57% received maintenance bevacizumab. Seventeen patients (11.3%; 95% CI 6.7-17.5%) experienced ≥1 perforation/fistula event gastrointestinal perforation/fistula in 4.7% (1.9-9.4%), gastrointestinal-vaginal fistula in 4.0% (1.5-8.5%), and genitourinary fistula in 4.7% (1.9-9.4%). Of these, 16 were previously irradiated, several with ongoing radiation effects. The most common grade 3/4 adverse events were neutropenia (25%), anemia (19%), and hypertension (14%). Five patients (3%) had fatal adverse events. Objective response rate w
Like
Comment
Share
